Literature DB >> 25662498

Target-specific near-IR induced drug release and photothermal therapy with accumulated Au/Ag hollow nanoshells on pulmonary cancer cell membranes.

Mi Suk Noh1, Somin Lee2, Homan Kang3, Jin-Kyoung Yang4, Hyunmi Lee4, Doyk Hwang5, Jong Woo Lee5, Sinyoung Jeong6, Yoonjeong Jang7, Bong-Hyun Jun8, Dae Hong Jeong9, Seong Keun Kim5, Yoon-Sik Lee10, Myung-Haing Cho11.   

Abstract

Au/Ag hollow nanoshells (AuHNSs) were developed as multifunctional therapeutic agents for effective, targeted, photothermally induced drug delivery under near-infrared (NIR) light. AuHNSs were synthesized by galvanic replacement reaction. We further conjugated antibodies against the epidermal growth factor receptor (EGFR) to the PEGylated AuHNS, followed by loading with the antitumor drug doxorubicin (AuHNS-EGFR-DOX) for lung cancer treatment. AuHNSs showed similar photothermal efficiency to gold nanorods under optimized NIR laser power. The targeting of AuHNS-EGFR-DOX was confirmed by light-scattering images of A549 cells, and doxorubicin release from the AuHNSs was evaluated under low pH and NIR-irradiated conditions. Multifunctional AuHNS-EGFR-DOX induced photothermal ablation of the targeted lung cancer cells and rapid doxorubicin release following irradiation with NIR laser. Furthermore, we evaluated the effectiveness of AuHNS-EGFR-DOX drug delivery by comparing two drug delivery methods: receptor-mediated endocytosis and cell-surface targeting. Accumulation of the AuHNS-EGFR-DOX on the cell surfaces by targeting EGFR turned out to be more effective for lung cancer treatments than uptake of AuHNS-EGFR-DOX. Taken together, our data suggest a new and optimal method of NIR-induced drug release via the accumulation of targeted AuHNS-EGFR-DOX on cancer cell membranes.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Doxorubicin; Hollow-shells; Lung cancer; Photothermal therapy; Targeted drug delivery; Triggered release

Mesh:

Substances:

Year:  2015        PMID: 25662498     DOI: 10.1016/j.biomaterials.2014.12.036

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  7 in total

1.  Plasmonic Nanoparticles: Advanced Researches (II).

Authors:  Hyejin Chang; Sang Hun Lee; Jaehi Kim; Won-Yeop Rho; Xuan-Hung Pham; Dae Hong Jeong; Bong-Hyun Jun
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Renal Clearable Organic Nanocarriers for Bioimaging and Drug Delivery.

Authors:  Homan Kang; Julien Gravier; Kai Bao; Hideyuki Wada; Jeong Heon Lee; Yoonji Baek; Georges El Fakhri; Sylvain Gioux; Brian P Rubin; Jean-Luc Coll; Hak Soo Choi
Journal:  Adv Mater       Date:  2016-07-14       Impact factor: 30.849

3.  Theranostic Nanosystems for Targeted Cancer Therapy.

Authors:  Homan Kang; Shuang Hu; Mi Hyeon Cho; Suk Ho Hong; Yongdoo Choi; Hak Soo Choi
Journal:  Nano Today       Date:  2018-11-16       Impact factor: 20.722

Review 4.  Pharmacokinetics, pharmacodynamics and toxicology of theranostic nanoparticles.

Authors:  Homan Kang; Shrutika Mintri; Archita Venugopal Menon; Hea Yeon Lee; Hak Soo Choi; Jonghan Kim
Journal:  Nanoscale       Date:  2015-11-03       Impact factor: 7.790

5.  Near-infrared light-mediated photodynamic/photothermal therapy nanoplatform by the assembly of Fe3O4 carbon dots with graphitic black phosphorus quantum dots.

Authors:  Ming Zhang; Wentao Wang; Yingjun Cui; Ninglin Zhou; Jian Shen
Journal:  Int J Nanomedicine       Date:  2018-05-10

Review 6.  Recent Advances in Surface-Enhanced Raman Scattering Magnetic Plasmonic Particles for Bioapplications.

Authors:  Kim-Hung Huynh; Eunil Hahm; Mi Suk Noh; Jong-Hwan Lee; Xuan-Hung Pham; Sang Hun Lee; Jaehi Kim; Won-Yeop Rho; Hyejin Chang; Dong Min Kim; Ahruem Baek; Dong-Eun Kim; Dae Hong Jeong; Seung-Min Park; Bong-Hyun Jun
Journal:  Nanomaterials (Basel)       Date:  2021-05-04       Impact factor: 5.076

Review 7.  The Application of Inorganic Nanoparticles in Molecular Targeted Cancer Therapy: EGFR Targeting.

Authors:  Meng Sun; Ting Wang; Leijiao Li; Xiangyang Li; Yutong Zhai; Jiantao Zhang; Wenliang Li
Journal:  Front Pharmacol       Date:  2021-07-12       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.